Announced Sat, 28 Jun · 18:54 IST

Intimation for closure of trading window for the quarter ended june 30, 2025.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Shukra Pharmaceuticals has informed BSE that its trading window will be closed starting Tuesday, July 1, 2025, and will remain shut until 48 hours after the company declares its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26). During this period, promoters, promoter group members, directors, key managerial personnel, insiders, designated persons, connected persons, and their immediate relatives are prohibited from trading in the company's shares. This is a standard compliance measure under SEBI's Insider Trading Regulations, 2015, and the company's own insider trading code. The date of the board meeting to approve the Q1 results has not yet been announced and will be communicated separately.

Likely market impact

This is a routine regulatory filing with no direct impact on the stock price. However, it signals that the company is preparing to announce its Q1 FY26 results soon, which investors should watch for. Until the window reopens (48 hours after results), insider-related share transactions will be restricted.